Biolase, Inc.

BIOL

Valor de mercado US$ 4,31 mi

LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b).

BIOLASE, Inc. (NASDAQ:BIOL ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Michael Polyviou - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.

Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.

LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.

BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year. 2023 Full-Year Highlights Achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.

LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.

Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.

LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas.

LAKE FOREST, CA / ACCESSWIRE / February 15, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit was sold at an effective public offering price of $0.44.